ClinicalTrials.gg
Not yet recruitingNCT07386795Updated Nov 18, 2026

The Efficacy and Safety of Microbiota Transplantation Combined With Prebiotics for Treatment of Functional Constipation

An interventional study of FMT in Constipation - Functional, Chronic Constipation and Fecal Microbiota Transplantation, sponsored by Peking Union Medical College Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Peking Union Medical College Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Nov 18, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 109 studies in Constipation with a site in China — 35 open to participants now, 37 under way, 1 of them phase 3. Constipation · China.

Planned enrollment
86th of 93
31 · median 100
Started
2026
with 10 others
No phase
56 of 109
21 open now
Primary completion
2027-07
later than 27 of 36 live
Registered
99th of 109
by date
Lead sponsor
4 of 109
Peking Union Medical College Hospital

Among the 109 studies in Constipation with a site in China, this one is the 86th largest by planned enrollment of the 93 interventional ones that give a count, is one of 11 that started in 2026, is one of 56 with no phase, reaches primary completion later than 27 of the 36 other live ones, and was the 99th registered.

Constipation

1,051 studies on the registry are indexed under Constipation; 163 are open to participants now.

Browse Constipation studies →

Open to participants now

35 of the 109 studies in Constipation with a site in China are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies in Constipation with a site in China, or all of them as a file.
02

Study summary

Chronic constipation is a common gastrointestinal disorder with a global prevalence of approximately 15%, severely impacting daily life and quality of life. It also increases the mortality rate from hypertension, cardiovascular diseases, and ischemic stroke, and is closely related to the incidence of colorectal cancer, making it a major chronic disease that seriously threatens people's health and quality of life. With the increasing aging population and lifestyle factors such as sedentary behavior and low-fiber diets, the incidence of functional constipation is gradually rising. Traditional treatment of chronic constipation mainly relies on various types of laxatives, which have significant side effects with long-term use and relatively high treatment costs, while surgical treatment has limited patient acceptance. Gut microbiota is closely related to intestinal motility, and patients with chronic constipation often have gut microbiota dysbiosis, with significant differences in gut microbiota diversity and colonic mucosal microbiota structure compared to healthy individuals. In recent years, more and more studies have found that intestinal microbiota-based therapies such as probiotics, prebiotics, synbiotics, postbiotics, and fecal microbiota transplantation (FMT) can effectively prevent and treat chronic constipation. FMT, as a method to reshape the gut microbiota, has been widely used in many centers at home and abroad, for diseases including inflammatory bowel disease, irritable bowel syndrome, autism, and obesity. The overall adverse reaction rate in clinical applications is approximately 3%, mainly consisting of abdominal discomfort (bloating, abdominal pain), diarrhea, and secondary intestinal infections or even bacteremia (rare). Our center has established a fecal microbiota transplantation center at Beijing Sixth Hospital within our medical alliance. We have currently performed nearly 100 cases of FMT for the treatment of IBD, autism, functional bowel diseases, and other metabolic diseases, with a clinical efficacy rate of 64-85% for functional constipation and constipation-predominant irritable bowel syndrome. This project aims to validate an intervention strategy combining fecal microbiota transplantation (FMT) with prebiotics primarily composed of high dietary fiber, based on the theoretical framework developed by the team led by Diwei Zheng at the Institute of Process Engineering, Chinese Academy of Sciences.The team found that the core microbiota playing a major role in the FMT process determines the therapeutic efficacy of FMT on diseases.These core microbial communities can produce acetic acid and butyric acid, which are important metabolites that not only reduce inflammatory levels and improve intestinal barrier function, but also provide energy for intestinal epithelial cells. Additionally, they effectively limit the growth of opportunistic pathogens by acidifying the intestinal environment, exerting antibacterial effects, and utilizing niche effects.Therefore, when the core microbiota occupies a dominant ecological niche in the gut, the gut microbiota can support health from multiple aspects including nutrition, immunity, metabolism, and psychology. Prebiotics designed based on the characteristics of the core microbiota can significantly enhance the activity and colonization of the core microbiota.This study aims to reconstruct a healthy intestinal ecosystem through FMT and prebiotics. Simultaneously, it proposes a "co-localization" strategy, which involves physically mixing prebiotics with core microbiota during transplantation to coexist synergistically. This approach enhances the metabolic function of core microbiota more efficiently locally, promotes the production of key metabolites such as acetic acid and butyric acid, and improves the intestinal microenvironment.Compared with the traditional stepwise model of 'microbiota transplantation + prebiotic intervention', this approach can significantly reduce the dosage of prebiotics, thereby further enhancing the safety and tolerability of the intervention.This clinical study is designed as an open-label, single-arm trial, aiming to enroll 19 patients with refractory functional constipation to receive "core microbiota transplantation based on co-localization".The study will focus on evaluating the therapeutic efficacy of the treatment in improving constipation symptoms, systematically assessing its safety, and comprehensively evaluating the level of gut microbiota remodeling through microbiome and metabolome approaches.The implementation of this project will provide clinical evidence for exploring the application of core microbiota therapy in functional bowel disorders such as constipation, and lay the foundation for optimizing and promoting microecological intervention strategies.

03

Conditions studied

  • Constipation - Functional
  • Chronic Constipation
  • Fecal Microbiota Transplantation

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with functional constipation (FC) according to Rome IV criteria.
  • Symptoms persisting for at least 6 months, with criteria met for the last 3 months.
  • Ineffective response to traditional treatments (dietary intervention, at least 2 types of laxatives, or probiotics).
  • Willing to discontinue other constipation medications, herbal medicines, or supplements during the study.

Exclusion criteria

Exclusion Criteria:

  • History or clinical evidence of mechanical bowel obstruction (e.g., tumor or hernia).
  • Diagnosis of megarectum, megacolon, or pseudo-obstruction.
  • Organic intestinal abnormalities (obstruction, stenosis, cancer) or inflammatory bowel disease (IBD).
  • Progressive colorectal polyps requiring treatment.
  • History of gastrointestinal or abdominal surgery within the past 3 months.
  • Severe cardiovascular or cerebrovascular diseases.
  • liver function abnormalities (/AST > 2x , ≥ 1.5x ULN).
  • Pregnancy, lactation, or planning to conceive during the study.
  • Inability to undergo colonoscopy or catheter placement.
  • Participation in other clinical trials within the past 3 months.
  • Other health conditions deemed unsuitable by the investigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (estimated)

Study arms

  • Experimental
    Fecal Microbiota Transplantation (FMT) combined with Prebiotics

    Participants will receive a "co-localization" intervention combining Fecal Microbiota Transplantation (FMT) and prebiotics. The FMT graft is derived from screened healthy donors and processed to ensure a total viable bacterial count of ≥ 2.5×10¹² CFU. Before administration, the microbiota is physically mixed and resuspended with the prebiotic preparation according to standard procedures to enhance colonization and metabolic function.

    Procedure: FMT

Interventions

  • ProcedureFMT

    In this group, antibiotics are administered for 3 days prior to the procedure. A colonoscopy is performed, and a catheter is placed in the ileocecal region. Bacterial infusion is performed for 3 days with 100 mL graft per day. The graft is prepared using a "co-localization" strategy: before infusion, the microbiota is physically mixed and resuspended with the prebiotic preparation according to standard procedures. Blood and stool samples are collected before and after fecal microbiota transplantation (FMT), and researchers conduct follow-up evaluations of the patients' abdominal symptoms and signs.

06

What researchers measure

Primary outcomes

  1. Change in complete spontaneous bowel movements (CSBM)

    Effect of FMT combined with prebiotics preparation on the change in complete spontaneous bowel movements (CSBM) of refractory functional constipation

    Time frame: 4 weeks

Secondary outcomes

  1. Frequency of SBM and CSBM

    Number of Spontaneous Bowel Movements (SBM) and Complete Spontaneous Bowel Movements (CSBM) per week.

    Time frame: Baseline through Week 8

  2. Bristol Stool Form Scale (BSFS) Score

    Assessment of stool consistency using the BSFS (scale 1-7).

    Time frame: Baseline through Week 8

  3. Patient Assessment of Constipation Symptoms Score

    Self-evaluation of constipation symptom severity.

    Time frame: Baseline, Week 4, and Week 8

  4. Colonic Transit Time

    Assessed by colonic transit test to evaluate intestinal motility.

    Time frame: Baseline and Week 4

  5. Fecal Water Content and Microbiota Composition

    Measurement of fecal water percentage and analysis of gut microbiota structure.

    Time frame: Baseline, Week 4, and Week 8

  6. Incidence of Adverse Events

    Number of participants with adverse events (e.g., bloating, infection).

    Time frame: From enrollment through Week 8

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jul 2027, 7 months later.

Of 246 non-industry interventional studies with no phase under Constipation, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 35. This study's planned 7 months is below that.

Counting every sponsor, half of 317 studies reached it within 14 months; a quarter within 6 and three quarters within 28.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Feb 2026 → Dec 2026, primary completion Nov 2026 → Jul 2027 and completion Dec 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2026
First posted
Feb 4, 2026
StartEst.
Dec 1, 2026was Feb 2026
Primary completionEst.
Jul 1, 2027was Nov 2026
CompletionEst.
Sep 1, 2027was Dec 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Feb 1, 2026→Dec 1, 2026
Nov 18, 2026
Primary completion
Nov 1, 2026→Jul 1, 2027
Nov 18, 2026
Study completion
Dec 31, 2026→Sep 1, 2027
Nov 18, 2026
Enrollment
19→31
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Start date Feb 1, 2026→Dec 1, 2026
    Primary completion Nov 1, 2026→Jul 1, 2027
    Study completion Dec 31, 2026→Sep 1, 2027
    Enrollment 19→31
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07386795
Collaborators
Chinese Academy of Sciences
Responsible party
Sponsor
First posted
Feb 4, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Jul 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Pengguang Yan
Contact
pengchengf@mail.sdu.edu.cn
+8618810309887
Jingnan Li, MD, Ph.D
study chair · Peking Union Medical College Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion